ArticleMolecular diversity2026
Computational discovery and validation of 4'-O-methylochnaflavone as a novel HSP90AB1 inhibitor for hepatocellular carcinoma treatment.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Saccharin Aggravates Eosinophilic Esophagitis via MAPK3 Interaction: A Network Toxicology and Machine Learning Study With SPR Analysis.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a global health issue with limited therapeutic efficacy. Heat shock proteins (HSPs) could enhance adaptation to the oxygen-deprived tumor microenvironment (TME), leading to chemotherapy resistance. Regulating HSP to improve the immune microenvironment may enhance tumor treatment efficacy. However, pharmacological agents targeting HSPs to reverse the immunosuppressive TME remain scarce. In this study, we integrated bioinformatic analysis, virtual screening, molecular docking, molecular dynamics (MD) simulations, and experimental validation to identify therapeutic targets and potential natural product-derived inhibitors. Differentially expressed hypoxia-related immune genes (HRIGs) associated with HCC prognosis were first identified using bioinformatic analysis. Venn diagram revealed HSP90AB1 as the candidate target protein. Virtual screening of the TargetMol and MedChemExpress (MCE) compound libraries was performed, and preliminary molecular docking identified 4'-O-methylochnaflavone as the lead compound. The interaction between 4'-O-methylochnaflavone and HSP90AB1 was further evaluated by MD simulations and experimental validation. Surface plasmon resonance (SPR) assay demonstrated that 4'-O-methylochnaflavone could stably bind HSP90AB1. In vitro CCK-8 assays demonstrated that 4'-O-methylochnaflavone inhibited Hep3B cell proliferation in a time- and dose-dependent manner. Finally, Western blot analysis confirmed hypoxia-induced upregulation of HSP90AB1, which was significantly suppressed by 4'-O-methylochnaflavone. In conclusion, our study identifies 4'-O-methylochnaflavone is a promising HSP90AB1-targeting therapeutic candidate for HCC treatment.
Indexed as
Identifiers
41073620What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.